|
Pharmax Ogilvy Healthworld |
CRA¸ðÁý (´ë¸® °úÀå±Þ)
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
ä¿ë½Ã |
09.29 |
|
|
Pharmax Ogilvy Healthworld |
CRA ¸ðÁý(´ë¸®°úÀå±Þ)
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
09.20 |
|
|
Ä¿¸®¾îHR |
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
¿¬±¸/¿¬±¸±âȹ |
1³â¡è |
ä¿ë½Ã |
12.03 |
|
|
¿òÆ® |
ÀÓ»ó½ÃÇè CRM (Clinical Research Manager) °æ·ÂÁ÷ ä¿ë
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
4³â¡è |
ä¿ë½Ã |
05.19 |
|
|
À¯´Ï¸ÞµåÁ¦¾àÁÖ½Äȸ»ç |
ÀÓ»óÇмúÆÀ ÀÓ»óÆÄÆ® °æ·ÂÁ÷ ¸ðÁý
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
02.16 |
|
|
(ÁÖ)Áö¿¡½º½ºÅÄ´Ùµå |
CRA, PMä¿ë
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
02.12 |
|
|
(ÁÖ)½Ã¹ÍÄÚ¸®¾Æ |
(ÁÖ)½Ã¹ÍÄÚ¸®¾Æ CRA I, II, Sr. °æ·ÂÁ÷ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
11.28 |
|
|
½ÃÁö¹ÙÀÌ¿À |
½ºÅÙÆ®TFT CRA ä¿ë °Ç
°æ±â ¼º³²½Ã Áß¿ø±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
»ó½Ãä¿ë |
01.09 |
|
|
PRA Health Sciences |
CRA, Sr. CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
04.18 |
|
|
PRA Health Sciences |
[PRA Health Sciences] CRA I, II, III, Drug Safety Associ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
06.28 |
|
|
(ÁÖ)¾¾¿£¾Ë¸®¼Ä¡ |
¾¾¿£¾Ë¸®¼Ä¡ °³², ºÎ»ê [°æ·Â] CRA ä¿ë
¼¿ï °³²±¸, ºÎ»ê ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
08.06 |
|
|
(ÁÖ)¸ÞµðÇïÇÁ¶óÀÎ |
¸ÞµðÇïÇÁ¶óÀÎ Àӻ󿬱¸ CR °æ·Â&½ÅÀÔ Ã¤¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.22 |
|
|
(ÁÖ)¾¾¿£¾Ë¸®¼Ä¡ |
¹ÙÀÌ¿À, ÀÓ»ó CRO [¾¾¿£¾Ë¸®¼Ä¡] ºÎ»ê »çºÎ¼Ò CRA ä¿ë
ºÎ»ê ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
07.13 |
|
|
(ÁÖ)Çѱ¹ÀǾ࿬±¸¼Ò |
ÀÓ»ó¸ð´ÏÅ͸µ¿ä¿ø(CRA) °æ·Â»ç¿ø ¸ðÁý
°æ±â ¼º³²½Ã Áß¿ø±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
03.13 |
|
|
PRA Health Sciences |
[PRA Health Sciences] CRA I, II, III, Contract Represent
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
11.14 |
|